2026 年 4 月 17–22 日 · San Diego · 共 2429 条
4 人 · 5 条 · 8 篇摘要
当前热度 1·可比范围峰值 1（4月22日 01:00）·近 24 小时可比范围变化 –·当前参与者 2
TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases
Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella
Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis
Yi-Long Wu, Wen-Zhao Zhong, Li-Xu Yan, Keneng Chen, Wanpu Yan, Yongzhong Luo, Wenxiang Wang, Wenqun Xing, Xiaolong Yan, Lin Wu, Feng Yao, Dongsheng Yue, Naiquan Mao, Yu Qi, Bentong Yu, Jianji Guo, Jindan Kai, Yuejun Chen, Hui Wang, Qin Zhang, Lunxu Liu, Honghai Wang, Yuanyuan Ji, Yongtao Han, Yongxiang Song, Jianjun Xu, Wei Guo, Hongxu Liu, Di Ge, Hecheng Li, XiuJuan Qu, Jifang Yao, Junfeng Liu, Tingyan Zhong, Yanhua Huang, Li Song, Wei Shi
Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study
Hua Zhong, Haifeng Liu, Wei Zheng, Linlin Wang, Baogang Liu, Fangling Ning, Yongzhong Luo, Qiming Wang, Weiliang Zhu, Jianying Zhou, Qingwei Zhao, Ruoyu Wang, Xiang Li, Juan Li, Runbo Zhong, Yizhou Jin, Xiangru Mao, Jing Wang, Qingyuan Liu, Xiaoqing Zhang
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray
RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC
Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen
Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II
Geoffrey Liu, Jorge Nieva, Lyudmila Bazhenova, Chang-Min Choi, Qitao Yu, Shunichi Sugawara, Noriko Yanagitani, Filippo de Braud, Huijie Fan, Enriqueta Felip, Emilio Bria, Maurice Pérol, Feiwu Ran, Wei Wang, Xianyu Zhang, Michael Chen, Caicun Zhou
Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, Adrianus Johannes de Langen, Alice T. Shaw, Jonathan W. Riess, Marina Garassino, Elaine Shum, Christina S. Baik, Jessica R. Bauman, D. Ross Camidge, Chien-Chung Lin, Gee-Chen Chang, Dong-Wan Kim, Myung-Ju Ahn, Ji-Youn Han, Kiichiro Ninomiya, Ryo Ariyasu, Ross Andrew Soo, Sanjay Popat, Jürgen Wolf, Maria Rosario García Campelo, Vivek A. Upadhyay, Stephen V. Liu
当我们提出正确的问题时，我们将找到正确的答案。 @charlesrudin #sclc #esmo26 @OncoAlert @myESMO
#SCLC #lungcancer #ESMO26 @myESMO
@dr_yakupergun @SuyogCancer @myESMO @OncBrothers @KolPulseAI In my view, your opinions regarding DeLLphi-305 and IMforte are very sensible and very intelligent.Congrats! Unfortunately, #Tarlatamab is not for every patient, it cannot be administered in every setting, and it is not the most economical option. This must be taken into account.
暂无中文译文，显示英文原文。
This is fabulous news for ES-SCLC #SCLC #ESMO26
Richly deserved standing ovation for @sands_jacob setting a new standard for the treatment of ES-SCLC #ESMO26
暂无中文译文，显示英文原文。